Health Technology Assessments In Oncology: Crizotinib Case Study

Health Technology Assessments In Oncology: Crizotinib Case Study

2014 Value in health

Thivolet, M. | Kornfeld, A. | Toumi, M. | Volume: 17, Issue: 7, Pages: A661, Value, Adult,

Crizotinib (Xalkori®) was approved for the treatment of adults with non-small cell lung cancer (NSCLC). The objective of this study was to illustrate the divergence of Health Technology Assessments in oncology by comparing the decisions of the National Institute for Health and Care Excellence (NICE), the Federal Joint Committee (G-BA) and French National Authority for Health (HAS)

https://www.doi.org/10.1016/j.jval.2014.08.2424; 10.1016/j.jval.2014.08.2424